Drug Profile
Research programme: cancer immunotherapeutics - GlobeImmune
Alternative Names: GI-10000; GI-10001; GI-3000; GI-3001; GI-6200Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator GlobeImmune
- Developer Celgene Cellular Therapeutics; GlobeImmune
- Class Yeasts
- Mechanism of Action Epidermal growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (SC)
- 20 Apr 2009 Preclinical development of the GI 3000 and GI 10000 programmes is ongoing in the US
- 19 Apr 2009 Preclinical pharmacodynamics data in Cancer presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)